Skip to content
DataLookout
Menu

EPIRENCT07948200

Urinary DNA Methylation Testing (Bladder EpiCheck®) and Its Peri-operative Kinetics for the Prediction of Residual Disease at Second Transurethral Resection in T1 Non-muscle-invasive Bladder Cancer

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Diagnostic accuracy of Bladder EpiCheck® test at timepoint T2 for residual disease at second TURBt in T1 NMIBC patients.
Timeframe: Through study completion, an average of 2 years
Diagnostic accuracy of change EpiScore between the two subsequent timepoints T1 and T2.
Timeframe: Through study completion, an average of 2 years

Secondary (9)

Diagnostic accuracy of Bladder EpiCheck® test at timepoint T1
Diagnostic accuracy of urinary cytology at timepoints T1 and T2
Agreement at T1 and T2 between Bladder EpiCheck® and urinary cytology
Agreement between T1 and T2 of Bladder EpiCheck®;
Agreement between T1 and T2 of urinary cytology
Show 4 moreShow less
Diagnostic accuracy at T1 and T2 of the combination of Bladder EpiCheck® and urinary cytology, defined in two versions: (1) as negative when both are negative, (2) as negative when at least one is negative
Diagnostic accuracy in the previous settings for predicting high-grade disease, ≥ pT1, and/or concomitant Carcinoma in Situ (CIS) at second TURBt;
Diagnostic accuracy of alternative definitions of change in EpiScore
Change in positivity rate of Bladder EpiCheck® and urinary cytology between T1 and T2 among patients whose second TURBt is negative.

Arms and interventions

EPIREExperimental

Devices: Bladder EpiCheck

Sites

1 site in 1 country

  • Istituto Oncologico VenetoPadova, Italy/Padova, Italy